Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,606 recruiting studies in this area right now.
By phase
- Not applicable4,686
- Phase 21,188
- Phase 1568
- Phase 3457
- Phase 1/Phase 2368
- Phase 4229
- Phase 2/Phase 3110
Top conditions
- Colorectal Cancer479
- Pancreatic Cancer287
- Gastric Cancer283
- Hepatocellular Carcinoma256
- Esophageal Cancer189
- Rectal Cancer168
- Breast Cancer146
- Crohn Disease134
- Ulcerative Colitis129
- Hepatocellular Carcinoma (HCC)114
- Colon Cancer112
- Liver Cancer99
- Lung Cancer95
- Inflammatory Bowel Diseases94
- Pancreas Cancer91
- Ovarian Cancer89
- Esophageal Squamous Cell Carcinoma86
- Cystic Fibrosis77
Leading sponsors
- Fudan University101
- Sun Yat-sen University85
- Mayo Clinic75
- Chinese University of Hong Kong56
- Second Affiliated Hospital, Zhejiang University, School of Medicine56
- M.D. Anderson Cancer Center55
- Assistance Publique - Hôpitaux de Paris53
- Sixth Affiliated Hospital, Sun Yat-sen University51
- National Cancer Institute (NCI)49
- National Taiwan University Hospital45
Where studies are running
- California438
- Arizona190
- Texas140
- Alabama129
- Florida128
- New York120
- Massachusetts119
- Maryland88
- Ohio79
- Illinois69
Recruiting studies7,606 total
- NCT06407518Recruiting
Preoperative medicine for pain relief in colorectal cancer patients with sleep or anxiety issues
This trial tests whether taking a medicine called midazolam before surgery can help with pain after surgery in people with colorectal cancer who have trouble sleeping or feel anxious. You would receive the medicine as a drink before your operation.
Guangzhou, GuangdongAges 18–60 - NCT06860477RecruitingPhase 2
Freezing therapy plus targeted drugs vs. chemotherapy for advanced bile duct cancer
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06914674RecruitingPhase 2
Tamoxifen for advanced pancreatic SPTP
This trial tests whether tamoxifen, a hormone therapy drug, can shrink or slow down advanced solid pseudopapillary tumors of the pancreas (SPTP) that have estrogen and progesterone receptors. It may be an option for people whose tumors cannot be removed by surgery or have come back after other treatments.
ShanghaiAges 14–80 - NCT06914635Recruiting
Immunotherapy hub study for liver tumor patients
This trial is checking how the immune system works in people with primary liver cancer, looking at ways to prevent infections and manage the tumor. It is an observational study—meaning no new treatments are given—so it helps doctors learn more without adding extra medications.
Pavia, PaviaAges 18–90 - NCT06912815Recruiting
Ustekinumab and nutrition before Crohn's surgery
This trial tests if combining a drug called ustekinumab with a special liquid diet (semi-exclusive enteral nutrition) is as effective as using only the liquid diet to improve outcomes before Crohn's surgery.
Guangzhou, GuangdongAges 18–65 - NCT03716089Recruiting
Laparoscopic surgery for stomach GIST by tumor site
This trial studies whether doing laparoscopic surgery for stomach GISTs (gastrointestinal stromal tumors) works and is safe when the tumor is in a “favorable” versus “unfavorable” location. You might be eligible if your tumor is confirmed as GIST and doctors expect to remove it completely using keyhole surgery.
Fuzhou, FujianAges 18–75 - NCT06912828Recruiting
Genes and diet for IBS
This trial is studying whether your genes can predict how well a special diet will help your IBS symptoms. If you have moderate to severe IBS and no other diet-related conditions, you may be able to take part.
AthensAges 18–65 - NCT05904301Recruiting
Registry for autoimmune and autoinflammatory disease patients
This study builds a nationwide list (registry) of people with certain autoimmune or inflammation-related illnesses. It helps researchers understand these diseases better over time, which can guide future care.
YerevanAges Any age - NCT07216105RecruitingPhase 1
New immune cell treatment for advanced solid tumors
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Newport Beach, CaliforniaAges 18 years+ - NCT07219459RecruitingPhase 2
New drug combo for liver cancer after PD-1/PD-L1 treatment fails
This study tests three drugs (visugromab, nivolumab, lenvatinib) compared to a placebo plus lenvatinib for people with liver cancer (HCC) that cannot be removed or has spread, and who have already been treated with a PD-1/PD-L1 inhibitor without success. The goal is to see if the combination can help shrink tumors or slow the cancer.
Irvine, CaliforniaAges 18–100 - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
Phoenix, ArizonaAges 18 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Phoenix, ArizonaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Aurora, ColoradoAges 18 years+ - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT07212907Recruiting
Probiotic and Ginger for Stomach Discomfort
This trial tests whether a combination of probiotics and ginger can improve symptoms and quality of life for people with functional dyspepsia (a condition causing ongoing stomach discomfort). Participants will take the supplement for several weeks and report how they feel.
IstresAges 18 years+ - NCT07221253RecruitingPhase 3
Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Birmingham, AlabamaAges 18 years+ - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT06915961Recruiting
HE4 Protein and Lung Function in Cystic Fibrosis
This study looks at a protein in the blood (HE4) and how it relates to lung function in children with cystic fibrosis. It also tests a quality improvement plan to help manage CF. The goal is to find better ways to track and treat the disease.
Cairo, AbbasiaAges 6 years+
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,606 recruiting gastroenterology studies from the U.S. registry right now, out of 12,023 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.